VELA Investment Management LLC Buys 12,408 Shares of Supernus Pharmaceuticals, Inc. $SUPN

VELA Investment Management LLC raised its stake in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.2% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 61,703 shares of the specialty pharmaceutical company’s stock after buying an additional 12,408 shares during the quarter. VELA Investment Management LLC’s holdings in Supernus Pharmaceuticals were worth $2,870,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the stock. Bank of America Corp DE grew its holdings in Supernus Pharmaceuticals by 37.2% during the first quarter. Bank of America Corp DE now owns 714,226 shares of the specialty pharmaceutical company’s stock worth $36,918,000 after buying an additional 193,479 shares in the last quarter. Mystic Asset Management Inc. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $1,181,000. BlackRock Inc. bought a new position in Supernus Pharmaceuticals during the 2nd quarter valued at $434,871,000. Allworth Financial LP purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $2,357,000. Finally, Rice Hall James & Associates LLC purchased a new position in Supernus Pharmaceuticals during the 2nd quarter worth $22,800,000.

Wall Street Analysts Forecast Growth

SUPN has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (d+)” rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. Cantor Fitzgerald raised their price target on shares of Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an “overweight” rating in a research report on Thursday, July 9th. Zacks Research upgraded shares of Supernus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Thursday, August 6th. Finally, Wall Street Zen downgraded shares of Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, August 8th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Supernus Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $62.83.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock opened at $43.53 on Tuesday. The business’s fifty day simple moving average is $46.62 and its 200 day simple moving average is $48.34. The firm has a market capitalization of $2.53 billion, a P/E ratio of -22.67, a price-to-earnings-growth ratio of 0.80 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 12 month low of $42.45 and a 12 month high of $59.68.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business had revenue of $219.06 million during the quarter, compared to the consensus estimate of $205.31 million. During the same quarter last year, the company earned $0.40 EPS. The firm’s revenue for the quarter was up 32.4% compared to the same quarter last year. Analysts predict that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current fiscal year.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company’s marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.